If you're interested in broad exposure to the Large Cap Value segment of the US equity market, look no further than the First Trust Morningstar Dividend Leaders ETF (FDL), a passively managed exchange ...

And, most ETFs are very transparent products that disclose their ... Looking at individual holdings, Abbvie Inc (ABBV) accounts for about 4% of total assets, followed by Johnson & Johnson (JNJ ...

He is now chairman, president and CEO of Candid Therapeutics, which has debuted with a $370 million series A and a goal to ...

Sarfaraz K. Niazi, PhD, explains the FDA's new guidelines on post-approval changes for biosimilars, emphasizing the processes ...

Such sums made Amazon one of the nation’s top ad spenders last year, according to MediaRadar, along with Procter & Gamble, AbbVie ... but to do it in a transparent and ethical way,” says ...

But the risk of a serious side effect appears to be higher than previously known. By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and ...

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward ...

AbbVie's dividend growth has slowed, but new drugs are offsetting Humira's decline. The company's debt levels and payout ratio are high, but its shares screen as undervalued. Recent strategic ...

AbbVie shares are nearing $200, likely facing resistance and a potential pullback to test support between $175 and $185. Despite strong dividends and share buybacks, AbbVie’s higher P/E ratio ...